Combined Prostate Brachytherapy and Short-Term Androgen Deprivation Therapy as Salvage Therapy for Locally Recurrent Prostate Cancer After External Beam Irradiation

William W. Wong, Steven J. Buskirk, Steven E. Schild, Karin A. Prussak, Brian J. Davis

Research output: Contribution to journalArticle

56 Citations (Scopus)

Abstract

Purpose: We describe the treatment outcome in 17 patients who received combined salvage brachytherapy and short-term androgen deprivation therapy for local prostate cancer relapse after prior external beam irradiation. Materials and Methods: Median patient age was 68 years. Local relapse after external beam irradiation was confirmed by biopsy. Median prostate specific antigen at local relapse was 4.7 ng/ml. Five of the 17 patients were enrolled in a protocol combining androgen deprivation therapy with brachytherapy and the remaining men were treated off protocol. All patients received neoadjuvant androgen deprivation therapy for a median of 3 months, followed by ultrasound guided brachytherapy using 125I in 9 and 103Pd seeds in 8. Five patients also received adjuvant leuprolide for a median of 6 months. Biochemical failure was defined using the American Society for Therapeutic Radiology and Oncology definition. Toxicity was graded with a modified Radiation Therapy Oncology Group scale. Results: Median followup was 44 months. The actuarial 4-year biochemical control rate was 75%. Three patients died of intercurrent diseases. No prostate cancer mortality or local failure had occurred at last followup. One patient had bone metastasis. No clinical or treatment factor was associated with biochemical control. Grade 3 and 4 genitourinary toxicity developed in 7 (41%) and 1 patients (6%), respectively. Grade 2 and 3 gastrointestinal toxicity occurred in 5 (29%) and 1 patients (6%), respectively. Conclusions: Our series suggests that salvage brachytherapy and short-term androgen deprivation therapy can achieve biochemical control in select patients with local relapse after prior external beam irradiation. The major side effects are urinary complications, including grade 3 and 4 complications in 41% and 6% of cases, respectively.

Original languageEnglish (US)
Pages (from-to)2020-2024
Number of pages5
JournalJournal of Urology
Volume176
Issue number5
DOIs
StatePublished - Nov 2006

Fingerprint

Salvage Therapy
Brachytherapy
Androgens
Prostate
Prostatic Neoplasms
Therapeutics
Recurrence
Leuprolide
Radiation Oncology
Prostate-Specific Antigen
Seeds
Radiotherapy
Neoplasm Metastasis
Biopsy
Bone and Bones

Keywords

  • brachytherapy
  • local
  • neoplasm recurrence
  • prostate
  • prostatic neoplasms
  • salvage therapy

ASJC Scopus subject areas

  • Urology

Cite this

Combined Prostate Brachytherapy and Short-Term Androgen Deprivation Therapy as Salvage Therapy for Locally Recurrent Prostate Cancer After External Beam Irradiation. / Wong, William W.; Buskirk, Steven J.; Schild, Steven E.; Prussak, Karin A.; Davis, Brian J.

In: Journal of Urology, Vol. 176, No. 5, 11.2006, p. 2020-2024.

Research output: Contribution to journalArticle

Wong, William W. ; Buskirk, Steven J. ; Schild, Steven E. ; Prussak, Karin A. ; Davis, Brian J. / Combined Prostate Brachytherapy and Short-Term Androgen Deprivation Therapy as Salvage Therapy for Locally Recurrent Prostate Cancer After External Beam Irradiation. In: Journal of Urology. 2006 ; Vol. 176, No. 5. pp. 2020-2024.
@article{9e367aa9765142b584e32e1b40d25eef,
title = "Combined Prostate Brachytherapy and Short-Term Androgen Deprivation Therapy as Salvage Therapy for Locally Recurrent Prostate Cancer After External Beam Irradiation",
abstract = "Purpose: We describe the treatment outcome in 17 patients who received combined salvage brachytherapy and short-term androgen deprivation therapy for local prostate cancer relapse after prior external beam irradiation. Materials and Methods: Median patient age was 68 years. Local relapse after external beam irradiation was confirmed by biopsy. Median prostate specific antigen at local relapse was 4.7 ng/ml. Five of the 17 patients were enrolled in a protocol combining androgen deprivation therapy with brachytherapy and the remaining men were treated off protocol. All patients received neoadjuvant androgen deprivation therapy for a median of 3 months, followed by ultrasound guided brachytherapy using 125I in 9 and 103Pd seeds in 8. Five patients also received adjuvant leuprolide for a median of 6 months. Biochemical failure was defined using the American Society for Therapeutic Radiology and Oncology definition. Toxicity was graded with a modified Radiation Therapy Oncology Group scale. Results: Median followup was 44 months. The actuarial 4-year biochemical control rate was 75{\%}. Three patients died of intercurrent diseases. No prostate cancer mortality or local failure had occurred at last followup. One patient had bone metastasis. No clinical or treatment factor was associated with biochemical control. Grade 3 and 4 genitourinary toxicity developed in 7 (41{\%}) and 1 patients (6{\%}), respectively. Grade 2 and 3 gastrointestinal toxicity occurred in 5 (29{\%}) and 1 patients (6{\%}), respectively. Conclusions: Our series suggests that salvage brachytherapy and short-term androgen deprivation therapy can achieve biochemical control in select patients with local relapse after prior external beam irradiation. The major side effects are urinary complications, including grade 3 and 4 complications in 41{\%} and 6{\%} of cases, respectively.",
keywords = "brachytherapy, local, neoplasm recurrence, prostate, prostatic neoplasms, salvage therapy",
author = "Wong, {William W.} and Buskirk, {Steven J.} and Schild, {Steven E.} and Prussak, {Karin A.} and Davis, {Brian J.}",
year = "2006",
month = "11",
doi = "10.1016/j.juro.2006.07.008",
language = "English (US)",
volume = "176",
pages = "2020--2024",
journal = "Journal of Urology",
issn = "0022-5347",
publisher = "Elsevier Inc.",
number = "5",

}

TY - JOUR

T1 - Combined Prostate Brachytherapy and Short-Term Androgen Deprivation Therapy as Salvage Therapy for Locally Recurrent Prostate Cancer After External Beam Irradiation

AU - Wong, William W.

AU - Buskirk, Steven J.

AU - Schild, Steven E.

AU - Prussak, Karin A.

AU - Davis, Brian J.

PY - 2006/11

Y1 - 2006/11

N2 - Purpose: We describe the treatment outcome in 17 patients who received combined salvage brachytherapy and short-term androgen deprivation therapy for local prostate cancer relapse after prior external beam irradiation. Materials and Methods: Median patient age was 68 years. Local relapse after external beam irradiation was confirmed by biopsy. Median prostate specific antigen at local relapse was 4.7 ng/ml. Five of the 17 patients were enrolled in a protocol combining androgen deprivation therapy with brachytherapy and the remaining men were treated off protocol. All patients received neoadjuvant androgen deprivation therapy for a median of 3 months, followed by ultrasound guided brachytherapy using 125I in 9 and 103Pd seeds in 8. Five patients also received adjuvant leuprolide for a median of 6 months. Biochemical failure was defined using the American Society for Therapeutic Radiology and Oncology definition. Toxicity was graded with a modified Radiation Therapy Oncology Group scale. Results: Median followup was 44 months. The actuarial 4-year biochemical control rate was 75%. Three patients died of intercurrent diseases. No prostate cancer mortality or local failure had occurred at last followup. One patient had bone metastasis. No clinical or treatment factor was associated with biochemical control. Grade 3 and 4 genitourinary toxicity developed in 7 (41%) and 1 patients (6%), respectively. Grade 2 and 3 gastrointestinal toxicity occurred in 5 (29%) and 1 patients (6%), respectively. Conclusions: Our series suggests that salvage brachytherapy and short-term androgen deprivation therapy can achieve biochemical control in select patients with local relapse after prior external beam irradiation. The major side effects are urinary complications, including grade 3 and 4 complications in 41% and 6% of cases, respectively.

AB - Purpose: We describe the treatment outcome in 17 patients who received combined salvage brachytherapy and short-term androgen deprivation therapy for local prostate cancer relapse after prior external beam irradiation. Materials and Methods: Median patient age was 68 years. Local relapse after external beam irradiation was confirmed by biopsy. Median prostate specific antigen at local relapse was 4.7 ng/ml. Five of the 17 patients were enrolled in a protocol combining androgen deprivation therapy with brachytherapy and the remaining men were treated off protocol. All patients received neoadjuvant androgen deprivation therapy for a median of 3 months, followed by ultrasound guided brachytherapy using 125I in 9 and 103Pd seeds in 8. Five patients also received adjuvant leuprolide for a median of 6 months. Biochemical failure was defined using the American Society for Therapeutic Radiology and Oncology definition. Toxicity was graded with a modified Radiation Therapy Oncology Group scale. Results: Median followup was 44 months. The actuarial 4-year biochemical control rate was 75%. Three patients died of intercurrent diseases. No prostate cancer mortality or local failure had occurred at last followup. One patient had bone metastasis. No clinical or treatment factor was associated with biochemical control. Grade 3 and 4 genitourinary toxicity developed in 7 (41%) and 1 patients (6%), respectively. Grade 2 and 3 gastrointestinal toxicity occurred in 5 (29%) and 1 patients (6%), respectively. Conclusions: Our series suggests that salvage brachytherapy and short-term androgen deprivation therapy can achieve biochemical control in select patients with local relapse after prior external beam irradiation. The major side effects are urinary complications, including grade 3 and 4 complications in 41% and 6% of cases, respectively.

KW - brachytherapy

KW - local

KW - neoplasm recurrence

KW - prostate

KW - prostatic neoplasms

KW - salvage therapy

UR - http://www.scopus.com/inward/record.url?scp=33750359284&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33750359284&partnerID=8YFLogxK

U2 - 10.1016/j.juro.2006.07.008

DO - 10.1016/j.juro.2006.07.008

M3 - Article

C2 - 17070243

AN - SCOPUS:33750359284

VL - 176

SP - 2020

EP - 2024

JO - Journal of Urology

JF - Journal of Urology

SN - 0022-5347

IS - 5

ER -